Ukuhlukaniswa
I-Viekira Pak iyinhlanganisela yezidakamizwa ezihlanganisiwe ezisetshenziselwa ukutheleleka ukutheleleka okungapheli kwe- hepatitis C (HCV) . Iphakethe libandakanya i-Technivie yezidakamizwa ezihlanganisiwe (i-ombitasvir + paritaprevir + ritonavir) ehlanganiswe eceleni kwedasabuvir yezidakamizwa.
Izakhi zezidakamizwa i-ombitasvir, i-paritaprevir ne-dasabuvir yi-anti-virus (i-DAA) eqondile ephazamisa ukuphindaphindiwe kwegciwane.
I- ritonavir yezidakamizwa, esetshenziselwa njalo ekwelashweni kwe-HIV , ifakiwe ukukhulisa amazinga omuthi we-paritaprevir.
I-Viekira Pak iningi, kodwa hhayi ngaso sonke isikhathi, ilawulwa yi- ribavirin futhi ayidingi ukuthathwa nge- interferon ye-pegylated (i-peg-interferon).
I-Viekira Pak yavunywa ngo-Disemba 19, 2014 yi-US Food and Drug Administration (FDA) ukuze isebenzise kubantu abadala kweminyaka engu-18 noma ngaphezulu nge-HCV genotypes 1 ukutheleleka, kuhlanganise nalabo abane- cirrhosis ehlisiwe (lapho isibindi sisasebenza) kanye nokufakelwa kwesibindi. Kulezi ziguli ezine-cirrhosis ezinikeziwe, i-Viekira Pak ayinconywa.
I-Viekira Pak ibikwa ukuthi inezinga lokuphilisa lama-95% noma ngaphezulu, kanti kuphela iziguli ezingu-2 kuphela eziqeda ukwelashwa ngenxa yokungabekezelelani. Kuyafaneleka ukusebenzisa iziguli ezine- HIV / HCV .
Isilinganiso
Amathebulethi amabili amathebhulethi ahlanganisiwe ombitasvir + paritaprevir + ritonavir (25mg / 150mg / 100mg) athathwa nsuku zonke ekuseni ngokudla, kanye netafula elilodwa le-dasabuvir ethathwe kabili nsuku zonke ekuseni nokuhlwa ngokudla.
Amaphilisi afika ngokulula ngezikhwebu ezinkampanini zamabhokisi nsuku zonke, nemiyalelo yokubuyisela efakwe ebhokisini ngalinye. Ithebhulethi eyenziwe ngokubambisana iyingqayizivele, ifilimu igcwele futhi ihlanganiswe ne "AV1", kuyilapho ithebhulethi ye-dasabuvir i-beige, icwecwe ifilimu futhi ibhalwe nge "AV2".
Ukubeka izincomo
I-Viekira Pak inqunywe ngaphezu kwenkambo yezinyanga ezingu-12 kuya ku-24, njengalezi zincomo ezilandelayo:
- I-Genotype 1a ngaphandle kwe-cirrhosis: Viekira Pak ne-ribavirin amasonto angu-12
- I-Genotype 1a nge-cirrhosis: Viekira Pak ne-ribavirin amasonto angu-24
- I-Genotype 1b ngaphandle kwe-cirrhosis: Viekira Pak yedwa ngamasonto angu-12
- I-Genotype 1b ngaphandle kwe-cirrhosis: Viekira Pak ne-ribavirin amasonto angu-24
Ukuze iziguli zokufakelwa kwesibindi, i-Viekira Pak ingathathwa ne-ribavirin amasonto angu-24 kuphela uma umsebenzi we-hepatic (isibindi) ujwayelekile futhi i-fibrosis (ukulaywa) incane.
Imiphumela Ejwayelekile Ejwayelekile
Imiphumela emibi kakhulu ehlobene nokusetshenziswa kwe-Viekira Pak (eyenzeka ngeziguli ezifika ku-10%) yilezi:
- Ukukhathala
- I-nausea
- Isikhumba esinamahloni
- Ukuthinta isikhumba
- Ukungalali
- Ubuthakathaka nokukhathala
Ukusebenzisana kwezidakamizwa
Okulandelayo kufanele futhi kugwenywe uma usebenzisa i-Viekira Pak:
- Anticonvulsants: carbamazepine, phenytoin, phenobarbital
- Ama-antihyperlipidemics (asetshenziselwa ukunciphisa amazinga e-lipid egazini): gemfibrozil
- Imithi yokulwa ne-anti-arrhythmia: i-pimozide
- Imithi yokwehla kwe-cholesterol: i-lovastatin, i-simvastatin
- Imithi yokuphuza erectile: i-Viagra (sildenafil)
- Imithi e-Ergot equkethe (isetshenziselwa ukwelapha ikhanda kanye nemigraines): i-ergotamine, i-dihydroergotamine, i- ergonovine, i-methylergonovine
- I-Ethinyl estradiol (ifomu eyenziwe ngumuntu nge-estrogen)
- Imithi ye-HIV : Sustiva (efavirenz) , Atripla (efavirenz + tenofovir + emtricitabine)
- Imithi ye-Hypotension: alfuzosin
- Imithi elwa namagciwane e-Rifampin: I-Mycobutin, i-Rifater, i- Rifamate, i-Rimactane, i- Rifadin, i-Priftin
- Ama-sedatives: i-triazolam, i-midazolam yomlomo
Ukungafani nokucabangela
Kulezi ziguli ezinokukhubazeka okulinganisiwe kwe-hepatic, i-Viekira Pak ayinconywa. I-Viekira Pak iphikisana ngokusetshenziswa kweziguli ezinokukhubazeka okukhulu kwe-hepatic.
I-Viekira Pak iphinde ihambisane nokusetshenziswa kwesiguli ngokuxilongwa okuyaziwayo ku-ritonavir (kuhlanganise no-Stevens-Johnson Syndrome, isifo esingaba sengozini, isisindo sonke sokuvuvukala komzimba).
I-Viekira Pak iphikisana nokusetshenziswa kwabesifazane abakhulelwe uma isetshenziswe ne-ribavirin.
Kunconywa ukuthi bonke abesifazane abaneminyaka yobudala ababelethwe yingane kumele bahlolwe njalo ngenyanga ngokukhulelwa ngesikhathi sokulashwa. Kunconywa ukuthi isiguli kanye nomlingani wakhe wesilisa banikezwe okungenani izindlela ezimbili ezingekho ze-hormonal zokuvimbela ukukhulelwa, nokuthi zisetshenziswe ngesikhathi sokulashwa kanye nezinyanga eziyisithupha emva kwalokho.
Umthombo:
I-US Food and Drug Administration (FDA). "I-FDA ivumela i-Viekira Pak ukuthi ilaphe isifo sofuba." I-Silver Spring, e-Maryland; ukushicilelwa okukhishwe ngoDisemba 19, 2014.